What kind of medicine is Quizatinib and how much does a box cost?

Quizartinib (Quizartinib, trade name Vanflyta, is an oral, small molecule receptor tyrosine kinase inhibitor specifically designed to treat adult patients with acute myeloid leukemia (AML) carrying FLT3-ITD (FMS-like tyrosine kinase 3 internal tandem repeats) mutations. This drug effectively inhibits the proliferation and survival of leukemia cells by targeting the activity of FLT3 kinase and blocking the cell signaling pathway driven by FLT3-ITD mutations.

FLT3-ITD mutation is one of the common molecular abnormalities in AML, and its presence is often closely associated with poor prognosis of the disease. As a second-generation FLT3 inhibitor, quizartinib has higher selectivity and stronger inhibitory activity than the first-generation inhibitor, and can achieve therapeutic effects at lower concentrations while reducing off-target toxicity and side effects.

In clinical applications, quizartinib is often used in combination with standard chemotherapy regimens as induction and consolidation therapy for newly diagnosed patients with FLT3-ITD-positive AML, as well as maintenance monotherapy after consolidation chemotherapy. This combined treatment regimen can significantly improve the overall survival and progression-free survival of patients, bringing new treatment hope to AML patients.

The recommended dosage and administration of quizartinib will be based on the patient's specific condition, physical condition, and tolerance. Patients need to use it under the guidance of a professional doctor and follow the doctor's recommendations and monitoring plan to ensure the safety and effectiveness of the treatment. At the same time, patients also need to pay attention to drug interactions and potential side effects, such as nausea, vomiting, diarrhea, abnormal electrocardiogram, etc., and promptly inform the doctor of any discomfort or abnormal symptoms.

Currently, Quizartinib is not yet available in China, and domestic patients have no way to purchase Quizartinib directly. It is understood that there are versions of Quizartinib marketed overseas. The original version marketed in Europe has a specification of 17.7mg*28 tablets and the price is about 80,000 yuan. The generic version marketed in Laos is marketed by Lucius Laos, and the specification is 17.7mg*14 tablets and the price is about 1,800 yuan.

In general, quizartinib is an effective targeted therapy for FLT3-ITD-positive AML patients. Its emergence provides new treatment options and hope for AML patients.

xa0

Reference materials:https://www.vanflytahcp.com/en/about-vanflyta